Jha Jay Prakash, Sinha Dinesh Kumar, Singh Sanjeet, Kumari Rekha
Department of Biochemistry, Indira Gandhi Institute of Medical Sciences, Patna, India.
Department of Oncology, Indira Gandhi Institute of Medical Sciences, Patna, India.
Asian Pac J Cancer Prev. 2025 Apr 1;26(4):1181-1187. doi: 10.31557/APJCP.2025.26.4.1181.
This study aims to evaluate the efficiency and accuracy of microRNA (miR)-486-5p as a screening and diagnostic tool for chronic myeloid leukemia (CML).
The study was performed on K562 cell line. The cell line of the erythroleukemia type originated from a 53-year-old female patient suffering from chronic myelogenous leukemia during a blast crisis. The cells are non-adherent, rounded in shape, and positive for the BCR: ABL1 fusion gene. In addition, we measured the expression of miR-486-5p in peripheral blood monocytes from healthy volunteers and compared the result with Imatinib treated and untreated K562 cell line.
As compared to control blood cells from healthy volunteers, there was a statistically significant downregulation of the expression of miR-486-5p in untreated K562 cells (p-value = 0.007). After Imatinib exposure, the miR-486-5p expression was significantly upregulated in K562 cells as compared to treated and untreated K562 cells (p-value = 0.004).
Numerous reports demonstrate the role of miRNA in acting as oncogenes or tumor suppressors in various cancers. We have reported an alteration in the expression of miR-486-5p in the CML cell line. The upregulation of miR-486-5p expression in the post-imatinib exposure K562 cell line suggests that miR-486-5p has an onco-suppressor effector role in the BCR-ABL downstream signalling pathway. It is possible to investigate miR-486-5p as a potential biomarker for early CML detection.
本研究旨在评估微小RNA（miR）-486-5p作为慢性髓性白血病（CML）筛查和诊断工具的效率和准确性。
本研究在K562细胞系上进行。该红白血病细胞系源自一名53岁患有慢性粒细胞白血病急变期的女性患者。细胞不贴壁，呈圆形，BCR:ABL1融合基因呈阳性。此外，我们测量了健康志愿者外周血单核细胞中miR-486-5p的表达，并将结果与伊马替尼处理和未处理的K562细胞系进行比较。
与健康志愿者的对照血细胞相比，未处理的K562细胞中miR-486-5p的表达在统计学上显著下调（p值 = 0.007）。伊马替尼处理后，与处理和未处理的K562细胞相比，K562细胞中miR-486-5p的表达显著上调（p值 = 0.004）。
大量报告证明了miRNA在各种癌症中作为癌基因或肿瘤抑制因子的作用。我们报道了CML细胞系中miR-486-5p表达的改变。伊马替尼处理后的K562细胞系中miR-486-5p表达上调表明miR-486-5p在BCR-ABL下游信号通路中具有肿瘤抑制效应作用。有可能将miR-486-5p作为早期CML检测的潜在生物标志物进行研究。
